Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12982203 | 0.83 | ESR1 (0.38) | ESR1ESR2SLC6A2TAAR1 | |
| SCHEMBL4430003 | 0.80 | MEN1 (0.46) | ESR1ESR2SLC6A2TAAR1LMNA | |
| SCHEMBL23005 | 0.78 | ESR1 (0.52) | ESR1ESR2SLC6A2TAAR1HTR2A | |
| SCHEMBL9876711 | 0.77 | TRPA1 (0.32) | — | |
| SCHEMBL28040853 | 0.76 | ESR1 (0.50) | ESR1ESR2SLC6A2TAAR1HTR2A | |
| SCHEMBL4352224 | 0.76 | SLC6A2 (0.56) | SLC6A2TAAR1LMNACYP2D6 | |
| SCHEMBL14350828 | 0.76 | TP53 (0.42) | ESR1ESR2SLC6A2TAAR1HTR2A | |
| SCHEMBL12981330 | 0.75 | — | — | |
| SCHEMBL1031401 | 0.74 | ESR1 (0.38) | ESR1ESR2SLC6A2TAAR1HTR2A | |
| SCHEMBL19243711 | 0.74 | ESR1 (0.39) | ESR1ESR2SLC6A2TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | claimed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| EP-0888262-B1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| CN-1140485-C | Cycloalkyl derivatives and solid-phase synthesis thereof | BASF | 2004-03-03 | — | — | CN | disclosed |
| CN-1131233-C | Carbohydrate derivatives and their solid-phase synthesis | BASF AG (DE) | 2003-12-17 | — | — | CN | disclosed |
| US-6521780-B1 | Cycloalkylmalonic ester derivatives as potential active substances in the drugs and crop protection; combinatorial chemistry | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-0906324-B1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AG (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6242583-B1 | COUPLING CARBOHYDRATE COMPOUNDS IN PRESENCE OF PROMOTER TO A FUNCTIONALIZED SOLID SUPPORT | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-05 | — | — | US | disclosed |
| CN-1219937-A | Carbohydrate derivatives and their solid-phase synthesis | BASF AG (DE) | 1999-06-16 | — | — | CN | disclosed |
| CN-1218448-A | Cycloalkyl derivatives and solid-phase synthesis thereof | BASF AG (DE) | 1999-06-02 | — | — | CN | disclosed |
| EP-0888262-A1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034852-A1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-25 | — | — | WO | disclosed |
| US-4713186-A | PHOSPHATE AND GRAPHITE OR INTERCALATION COMPOUND | LONZA LTD. (CH) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | ESR1 4791/4885ESR2 4671/4885SLC6A2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.